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Abstract 
Background: CDK 4 and 6 inhibitors (CDK4/6i), which arrest unregulated cancer cell 
proliferation, show clinical efficacy in breast cancer. Unexpectedly, a patient treated on a 
CDK4/6i-based trial, as first-line therapy in metastatic breast cancer, developed rapid disease 
progression following discontinuation of study drug while receiving standard second-line therapy 
off trial. We thus sought to expand this observation within a population of patients treated 
similarly at The University of Texas MD Anderson Cancer Center. 
Methods: Using an IRB-approved protocol, 4 patients previously enrolled on CDK4/6i trials were 
analyzed for outcomes after discontinuing study drug. These patients were treated on a 
randomized trial of first-line endocrine therapy +/- a CDK4/6i. Rapid disease progression was 
defined as progression occurring within 4 months of CDK4/6i discontinuation.  
Results: In total, 4 patients developed rapid disease progression and died; 2 of whom died within 
6 months of CDK4/6i discontinuation. 
Conclusion: This case series suggests a potential for rapid disease progression following CDK4/6i 
discontinuation. However, the clinical course following progression must be validated in large 
CDK4/6i clinical trials and standard-of-care cohorts. If confirmed, such observations may alter the 
algorithm for subsequent therapy in patients with disease progression on CDK4/6i. Nevertheless, 
the need remains to define a mechanistic basis for this rapid progression and formulate alternative 
therapeutic strategies. 
Key words: Breast Cancer; Estrogen Receptor-Positive Breast Cancer; Rapid Disease Progression; CDK and 
CDK Inhibitors 
Introduction 
In normal cellular division, various cyclin 
dependent kinases (CDKs) control the transition from 
one phase of the cell cycle to another by binding to 
cyclin protein subunits and overcoming specific 
molecular checkpoints. CDK4 and CDK6 (CDK4/6), 
in complex with the D class of cyclins, regulate the 
transition from the early G1 to late G1 phase, while 
cyclin E, in complex with CDK2, regulate the 
transition from the late G1 phase to the S phase. The 
key substrate for these two different complexes is the 
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retinoblastoma (Rb) protein, which is sequentially 
phosphorylated in early and late G1 by cyclin 
D1/CDK4/6, followed by cyclin E/CDK2 complexes. 
The resulting hyperphosphorylated Rb is deactivated, 
allowing the dividing cell to bypass the G1-S phase 
cell cycle checkpoint.  
Overexpression of the G1 cyclins accelerate the 
transition through the G1-S phase checkpoint, and the 
subsequent cellular proliferation impacts disease 
prognosis [1, 2, 3, 4]. CDK inhibitors arrest cellular 
proliferation in response to various conditions. 
Activating aberrations, such as gene amplification and 
translocation of cyclins, as well as loss of function of 
Rb and CDK inhibitors, are common in cancer, 
making CDKs logical cancer therapy targets [5]. 
Recently, selective CDK4/6 inhibitors (CDK4/6i) 
have been shown to block the growth of estrogen 
receptor-positive (ER+) breast cancer cell lines [6], but 
have low activity as single agents for the treatment of 
breast cancer [7]. Combining CDK4/6 inhibition 
(palbociclib) with endocrine therapy (letrozole) 
significantly improved progression-free survival 
(PFS) from 10.2 to 20.2 months (p=0.0004) when 
compared to letrozole alone as first-line therapy for 
the treatment of patients with advanced ER+, 
HER2-negative (ER+/HER2-) disease. This treatment 
combination had an acceptable toxicity profile, which 
included reversible neutropenia [8]. Although the 
study was not powered to assess overall survival 
(OS), the near doubling in PFS did not translate into 
significant improvement in OS, with a median of 37.5 
months for the letrozole plus palbociclib arm, and 33.3 
months in the letrozole alone arm (p=0.42). 
 At our institution, a patient with bone-only 
disease, who developed cyclic neutropenia, and also 
had prolonged disease stability for 12 months while 
treated on a randomized, double-blind trial of 
first-line hormone therapy +/- a CDK4/6i, was noted 
to have increased uptake on bone scans with a rising 
CA15-3, prompting study drug discontinuation and 
the initiation of second-line therapy with everolimus 
and exemestane. After 2 months of second-line 
therapy, the patient exhibited atypical, rapid disease 
progression which also included visceral organ 
involvement. Given this patient’s history of a 
well-controlled disease status while on study but 
rapid, secondary disease progression after only 2 
months of second-line therapy, we further explored 
the rate of rapid, secondary disease progression in 
other patients treated at our cancer center following 
CDK4/6i trial discontinuation. 
Methods 
 Using an IRB-approved protocol at the 
University of Texas MD Anderson Cancer Center, 
cases of patients who were removed from trials of 
hormone therapy +/- a CDK4/6i were identified and 
evaluated for patient outcomes during subsequent 
treatment after study discontinuation. Only patients 
who discontinued CDK4/6i therapy due to disease 
progression are included in this analysis. The data 
collected included the number of therapies received 
prior to entering the CDK4/6i clinical trial, 
subsequent treatment regimen after discontinuing 
CDK4/6i, start and stop dates for subsequent 
systemic therapy, reason for discontinuation, and date 
of last follow-up or patient death. One 
CDK4/6i-based clinical trial was identified with 
enrollment durations long enough to have patients 
who developed disease progression. This trial was a 
double-blind, first-line therapy trial of CDK4/6i 
versus placebo in combination with an aromatase 
inhibitor (AI) for the treatment of advanced 
ER+/HER2- breast cancer. Patients enrolled in this 
placebo-controlled trial were allowed, per protocol, to 
be unblinded if requested by the treating physician at 
the time of disease progression. All patients had blood 
counts followed routinely as per protocol. For the 
purposes of this analysis, those who were unblinded 
and found to be receiving CDK4/6i, as well as those 
who remained blinded but developed neutropenia 
while receiving protocol therapy, were considered to 
have received the CDK4/6i, as AI therapy alone is 
unlikely to result in Grade III neutropenia, defined as 
an absolute neutrophil count (ANC) below 1,000/uL 
[7, 9, 10].  
 Since time to treatment progression (TTP) 
approaches nine months in postmenopausal women 
receiving letrozole as first-line AI therapy [11], we 
defined rapid disease progression as progression that 
occurred within four months of CDK4/6i plus 
first-line AI discontinuation. Median duration of 
therapy on CDK4/6i trial was defined as the time 
from CDK4/6i trial initiation until trial 
discontinuation. TTP was defined as the time from 
CDK4/6i trial discontinuation until disease 
progression while receiving post CDK4/6i trial 
therapy. Post CDK4/6i survival was defined as the 
time from CDK4/6i trial discontinuation until the 
time of death, and OS as the time from CDK4/6i trial 
initiation until the time of death (Figure 1). 
Results 
At the time of this report, 15 patients had been 
treated on the first-line, randomized 
placebo-controlled trial, and 6 patients had 
discontinued therapy due to disease progression. 
None of the patients were removed from the trial for 
any reason other than disease progression. Three of 
these 6 patients were unblinded; the first had 
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neutropenia during therapy and found to have 
received the CDK4/6i, while the other two did not 
develop neutropenia and were found to be on the 
placebo arm of the trial. The remaining 3 patients, 
who were kept blinded following study 
discontinuation, developed neutropenia on trial and 
are presumed to have received the CDK4/6i for the 
purposes of this analysis (Table 1). 
 
Table 1: Patients Who Received First-line Hormone Therapy 
With a CDK4/6 Inhibitor 
Pt. Age Low 
ANC 
Cycles of 
CDK4/6i 
or 
Placebo 
Duration 
of 
Therapy 
(months) 
Post 
CDK4/6i 
Clinical Trial 
Therapy 
TTP1 
(months) 
Post 
CDK4/6i 
Survival 
(months) 
OS 
(months) 
1 42 Yes 12 11.70 Capecitabine 2.80 24.83 36.53 
2 49 Yes 12 11.60 Exemestane 
+ Everolimus 
2.10 5.20 16.80 
3 38 Yes 18 17.00 Exemestane 
+ Everolimus 
1.46 10.73 27.73 
4 50 Yes 9 8.40 Exemestane 
+ Everolimus 
2.60 3.70 12.10 
Median 12 11.65 N/A 2.35 7.97 22.32 
Legend/Abbreviations: Pt.: Patient, TTP1: Time to progression while receiving post 
CDK4/6i clinical trial therapy. 
 
 
 The median duration of therapy on trial was 
11.65 months. However, following CDK4/6i 
discontinuation, all 4 patients known or presumed to 
have received first-line AI therapy in combination 
with a CDK4/6i developed rapid disease progression 
and two patients died within 6 months of 
discontinuing the CDK4/6i (Table 1). Three of the 4 
patients were treated with exemestane and 
everolimus after CDK4/6i plus first-line AI 
discontinuation, while one patient received 
capecitabine. In spite of the fact that all patients 
developed rapid disease progression following 
CDK4/6i discontinuation, post CDK4/6i survival 
durations were varied, with Patients #2 and #4, who 
progressed rapidly on exemestane and everolimus, 
expiring in 5.20 and 3.70 months, respectively, while 
Patients #1 and #3, who rapidly progressed on 
capecitabine and exemestane and everolimus, 
respectively, proceeded to survive on subsequent 
lines of therapy for 24.83 and 10.73 months, 
respectively. 
Discussion 
 In early studies for the treatment of advanced 
ER+/HER2- breast cancer, CDK4/6i combined with 
AI showed very promising activity. However, after 
we observed one patient develop rapid, secondary 
disease progression in 63 days while receiving 
second-line everolimus and exemestane therapy 
following CDK4/6i trial discontinuation, we 
conducted a review of 4 patients to further 
characterize rapid disease progression after CDK4/6i 
cessation. 
As previously mentioned, Finn et al. (2015) [8] 
reported a significantly improved PFS from 10.2 to 
20.2 months after combining CDK4/6 inhibition 
(palbociclib) with hormone therapy (letrozole) when 
compared to letrozole alone as first-line therapy for 
the treatment of patients with advanced ER+, 
HER2-negative (ER+/HER2-) disease. However, 
although our patients received a CDK4/6i plus 
first-line hormone therapy, our reported cases did not 
show similar clinical benefit (median duration on trial 
of 11.65 months). Instead, these patients showed a 
clinical picture more consistent with single AI agent 
administration [11]. Nevertheless, when the CDK4/6i 
was discontinued, all 4 patients reflected this 
unanticipated, rapid, secondary disease progression 
on subsequent lines of therapy, which is the subject of 
this case series. Despite rapid disease progression, 
however, patients did not demonstrate consistent 
sensitivity or responsiveness to subsequent lines of 
therapy. Two of the three patients 
who rapidly progressed on 
exemestane and everolimus 
survived less than 6 months 
following CDK4/6i 
discontinuation, while the one 
patient who rapidly progressed 
on capecitabine and the third 
patient who rapidly progressed 
on exemestane and everolimus, 
survived for greater than 24 and 
10 months, respectively. Of note, 
one patient (data not shown) had 
been enrolled in a separate, 
open-label, single-arm trial of 
second or greater-line endocrine 
therapy plus a CDK4/6i and the 
 
 
Figure 1: Patient Timeline of CDK4/6i Trial Participation and Outcomes Definition. Legend: Duration of 
Therapy is defined as the time from CDK4/6i trial initiation until trial discontinuation. TTP: Time to treatment 
progression; defined as the time from CDK4/6i trial discontinuation until disease progression while receiving 
post CDK4/6i trial therapy. Post CDK4/6i survival is defined as the time from CDK4/6i trial discontinuation 
until time of death. OS: Overall Survival; defined as the time from CDK4/6i trial initiation until time of death. 
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mTOR inhibitor everolimus. After 8.5 months on this 
CDK4/6i-based trial, the patient progressed and was 
treated with MLN0128, an mTORC1/2 inhibitor, plus 
ziv-Aflibercept, a VEGF inhibitor. On this initial post 
CDK4/6i therapy, the patient developed a TTP of 4.10 
months, but then proceeded to respond on 
subsequent lines of therapy for over 20 months, and is 
still alive as of last follow up. Therefore, in addition to 
highlighting the phenomenon of rapid disease 
progression after CDK4/6i discontinuation, this case 
series also suggests that post CDK4/6i therapy may 
result in aberrant signaling pathways which confer 
primary resistance to certain therapies but not others, 
as occurred with Patients #2 and #4 and Patients #1 
and #3, respectively, as well as with the patient who 
received MLN0128 plus ziv-Aflibercept following 
CDK4/6i discontinuation. 
Additionally, patients who received exemestane 
as a second or greater-line therapy, in combination 
with everolimus in the pivotal BOLERO-2 trial, were 
shown to progress after 6.9 months of therapy [12], 
while our patient cohort who received exemestane, as 
second or greater-line therapy, plus everolimus 
following CDK4/6i discontinuation, had a median 
TTP of 2.1 months. Moreover, while our report 
focuses on a select group of patients with rapid 
disease progression on subsequent anti-estrogen 
therapy following CDK4/6i discontinuation, a recent 
follow-up analysis from the PALOMA-1/TRIO-18 
trial by Finn et al. (2016) [13] reported a similar 
median duration of subsequent endocrine therapy in 
both study arms (palbociclib plus letrozole versus 
letrozole alone), but does not address the issue of 
rapid disease progression as we did. Similarly, Turner 
et al. (2016) [14] investigated post treatment outcomes 
in patients who received palbociclib plus fulvestrant 
versus fulvestrant alone in the PALOMA-3 trial. In 
their analysis, the median duration on next-line 
therapy was 17.9 months in the palbociclib plus 
fulvestrant cohort [14], however they did not assess 
time to progression on next-line therapy according to 
therapy used. As our case series suggests that 
CDK4/6i therapy may confer primary resistance to 
specific next-line therapies, further analysis into post 
CDK 4/6i outcomes according to subsequent therapy 
used is warranted. 
After accounting for the effects of hormone 
therapy and everolimus, a greatly reduced TTP raises 
the issue of a specific CDK4/6i mechanism of 
resistance and/or the activation of a yet to be defined 
biological pathway that results from CDK4/6i 
withdrawal. In a recent study by Vijayaraghavan et al. 
(2017) [15], resistance to palbociclib was found to be 
related to the presence of retinoblastoma (Rb) and low 
molecular weight cyclin E (LMW-E), where higher 
levels of Rb and LMW-E in breast cancer cell lines 
greatly reduced sensitivity to palbociclib. Thus, 
although the underlying mechanisms of these clinical 
observations remains unknown, preclinical data may 
offer potential explanations not only for the rapid 
disease progression seen in certain patients following 
CDK4/6i discontinuation, but a better understanding 
as to which patients are less likely to respond to 
CDK4/6i prior to therapy initiation.  
Inhibition of CDK4/6 has been associated with 
senescence-autophagy transition (SAT) in stromal 
fibroblasts leading to mitochondrial dysfunction and 
catabolism. This process releases high-energy 
mitochondrial fuels (onco-catabolites) into the stroma, 
such as L-lactate, ketone bodies, and glutamine, 
which act to drive anabolic tumor growth and cancer 
metastasis [16, 17]. Indeed, when fibroblasts with 
induced senescence were co-cultured with 
MDA-MB-231 breast cancer cell lines, a near 2-fold 
increase in tumor growth, without increased 
angiogenesis, was noted as compared to control [16]. 
Thus, rapid progression following CDK4/6i 
discontinuation may be explained by the fact that 
although these onco-catabolites are generated in 
patients receiving CDK4/6i, their tumor-growing 
effects are silenced by the significant anti-proliferative 
properties of CDK4/6i during active therapy. When 
CDK4/6i are discontinued, however, the suppression 
of these onco-catabolites is released, potentially 
leading to rapid tumor progression.  
This hypothesis-generating report will need 
further investigation in larger patient cohorts, either 
by collecting subsequent therapy outcome data in 
existing CDK4/6i clinical trials, or by determining 
patient outcomes after the FDA-accelerated approval 
of palbociclib made the drug available to patients 
with advanced ER+/HER2- breast cancer. Of 
importance, patients in this series received an AI with 
mTOR inhibition following the discontinuation of a 
CDK4/6i clinical trial. Preclinical experiments have 
suggested that inhibition of cyclin D1, or its other 
binding partners to CDK4/6, enhance features of the 
epithelial-mesenchymal transition (EMT) and increase 
mobility in both breast and pancreatic cancer cell 
lines, which occurs predominantly through the 
activation of TGF-β, inducing Akt-TOR signaling [18, 
19]. Thus, while one may expect everolimus to play a 
role in overcoming this potential pathway of CDK4/6i 
resistance, its effects may not be observed following 
CDK4/6i discontinuation due to the presence of 
onco-catabolites and the establishment of a primed 
microenvironment that is highly conducive to rapid 
tumor growth. As such, continuation of CDK4/6 
inhibition may be necessary for maximal effect when 
considering a targeted therapy as subsequent 
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treatment after CDK4/6i. Additionally, biologic 
studies to identify patients at risk for developing 
rapid disease progression should also be pursued as 
these patients may need more aggressive monitoring 
for progression or require chemotherapy as 
subsequent therapy after CDK4/6i.  
Conclusion 
 The markedly shortened TTP observed in our set 
of patients who discontinued CDK4/6i raises 
concerns as to the effect of CDK4/6i on metastatic 
breast cancer disease biology. In addition to the 
observed phenomenon of rapid disease progression, 
response to subsequent therapies was found to be 
varied in patients, with two of the patients developing 
rapid disease progression after CDK4/6i withdrawal, 
but then proceeding to follow the expected natural 
history of disease (surviving 10.73 and 24.83 months 
after CDK4/6i discontinuation), and two patients 
developing rapid progression and then expiring in 
5.20 and 3.70 months after CDK4/6i discontinuation. 
As explanations for these unexpected disease 
outcomes remain largely unexplored, and the 
mechanisms leading to rapid disease progression 
have yet to be elucidated, such findings warrant 
further investigation using larger datasets and 
prospective outcome studies. 
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